Ignite Creation Date:
2024-05-05 @ 5:26 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00453323
Status:
UNKNOWN
Last Update Posted:
2010-07-12
First Post:
2007-03-27
Brief Title:
Paclitaxel and Capecitabine in Patients With MetastaticRecurrence Esophageal Cancer
Sponsor:
National Cancer Center Korea
Organization:
National Cancer Center Korea
Study Overview
Official Title:
A Phase II Study of Weekly Paclitaxel and Capecitabine in Patients With Metastatic or Recurrent Esophageal Cancer
Status:
UNKNOWN
Status Verified Date:
2010-07
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Capecitabine is an orally administered fluoropyrimidine that is converted by 5-FU by thymidine phosphorylase TP preferentially in tumor tissues and has demonstrated activity as single agent in patients with gastrointestinal cancer Up-regulation of TP after taxane treatment in vitro suggested that there may be synergistic effects in combined treatment with taxane and capecitabine The combination of taxane and capecitabine was reported to be highly active against non-small cell lung cancer breast cancer and stomach cancer
Detailed Description:
Paclitaxel-80 mgm2IV D1 D8 q 3 weeks Capecitabine-900 mgm2PO twice daily Days 1-14 q 3 weeks
Patients receive treatment every 3 weeks till disease progression
Patients receive treatment every 3 weeks till disease progression
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None